Results 31 to 40 of about 12,197 (188)
MicroRNA profiles following telmisartan treatment in pancreatic ductal adenocarcinoma cells [PDF]
, 2021 香川大学Kagawa University博士（医学）Background: Panereatic ductal adenocarcinoma (PDAC) is the most devastating of all cancers with an extremely poor prognosis. It has few effective and reliable therapeutic strategies.
Yamana, Yoshimi +2 more
core +2 more sources
Effects of telmisartan and ramipril on adiponectin and blood pressure in patients with type 2 diabetes [PDF]
, 2008 <b>Background:</b> Adiponectin is secreted by adipose tissue and may play a role in cardiovascular disease. We examined adiponectin levels in patients with type 2 diabetes who participated in the Telmisartan vs.
Fauvel, J.P. +11 more
core +2 more sources
Telmisartan increases hepatic glucose production via protein kinase C ζ-dependent insulin receptor substrate-1 phosphorylation in HepG2 cells and mouse liver [PDF]
Yeungnam University Journal of Medicine, 2019 Background Dysregulation of hepatic glucose production (HGP) contributes to the development of type 2 diabetes mellitus. Telmisartan, an angiotensin II type 1 receptor blocker (ARB), has various ancillary effects in addition to common blood pressure ...
Kae Won Cho, Du-Hyong Cho
doaj +1 more source
Cardiovascular Diabetology, 2012 Background Telmisartan is a well-established angiotensin II type 1 receptor blocker that improves insulin sensitivity in animal models of obesity and insulin resistance, as well as in humans. Telmisartan has been reported to function as a partial agonist
Shiota Asuka +12 more
doaj +1 more source
Studying Telmisartan Plasma Exposure, Kidney Distribution, Receptor Occupancy, and Response in Patients With Type 2 Diabetes Using [C-11]Telmisartan [PDF]
, 2022 The angiotensin receptor blocker telmisartan slows progression of kidney disease in patients with type 2 diabetes (T2D), yet many patients remain at high risk for progressive kidney function loss.
Slart, Riemer H. J. A. +22 more
core +2 more sources
SARTANS OF THE SECOND GENERATION: THERAPEUTIC POTENTIAL EXTENSION
Рациональная фармакотерапия в кардиологии, 2016 Peculiarities of the treatment with angiotensin II receptor blocker telmisartan are analyzed taking into account its clinical and pharmacological characteristics. Special attention is paid to the telmisartan benefits in comparison with other sartans. Key
S. V. Nedogoda
doaj +1 more source
Molecules, 2014 Telmisartan, a member of the angiotensin II type 1 receptor blockers, is usually used for cardiovascular diseases. Recent studies have showed that telmisartan has the property of PPARγ activation.
Juan Li +5 more
doaj +1 more source
Perspectives in Clinical Research, 2022 Background: Diabetes mellitus is a chronic noncommunicable disease, and hypertension (HT) is the most common comorbidity which affects their quality of life (QoL).
Raj Kumar Bhardwaj +6 more
doaj +1 more source
Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly [PDF]
, 2010 Bodh I JugduttDivision of Cardiology, Department of Medicine, University of Alberta and Hospital, Edmonton, CanadaAbstract: Elderly patients (age≥65 years) with hypertension are at high risk for vascular complications, especially when diabetes is ...
Bodh I Jugdutt, Bodh Jugdutt
core +1 more source
Journal of Pharmacological Sciences, 2014 Telmisartan, an angiotensin II type 1–receptor blocker (ARBs), has been reported to exert beneficial effects on the central nervous system (CNS). However, the effect of telmisartan on cognitive impairment associated with type 1 diabetes is not well known.
Guan Tao Du +9 more
doaj +1 more source